{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:01:47Z","timestamp":1768568507623,"version":"3.49.0"},"posted":{"date-parts":[[2025,4,22]]},"group-title":"Genetic and Genomic Medicine","reference-count":24,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) syndrome is an ultrarare inborn error of immunity caused by heterozygous, gain-of-function\n                  <jats:italic>CXCR4<\/jats:italic>\n                  mutations that impede leukocyte egress from bone marrow, resulting in panleukopenia. The CXCR4 antagonist plerixafor (AMD3100, Mozobil) durably reverses panleukopenia and in most WHIM patients induces wart regression; however, its short half-life requires twice daily injection. To develop a simpler, cheaper and potentially more effective method of drug delivery, we conducted a Phase 1 study of WHIM patients given plerixafor 0.02-0.08 mg\/kg\/d by continuous subcutaneous infusion using an OmniPod insulin pump, and assessed compliance as well as effects on blood leukocyte counts, infections, chronic skin conditions and adverse events. Six patients were treated for a total of 6.3 patient-years; one patient dropped out early for personal reasons. The drug infusion rate was adjusted to achieve a normal absolute lymphocyte count and an absolute neutrophil count &gt;500 cells\/\u00b5l in all patients. An average of 2.1 infections\/patient-year occurred (range 0-4). Treatment of two infections involved brief hospitalization. On plerixafor, partial wart regression occurred in 3 of 4 patients, a single molluscum contagiosum infection regressed and a chronic post-Mohs surgical wound epithelialized. There were 3 serious adverse events, but none was attributable to the treatment. All patients preferred pump administration over syringe injection. Thus, in WHIM patients a continuous infusion pump may be a convenient, safe and potentially cost-effective means of delivering plerixafor chronically to correct panleukopenia and to improve chronic skin conditions.\n                  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00967785\">NCT00967785<\/jats:ext-link>\n                  .\n                <\/jats:p>","DOI":"10.1101\/2025.04.19.25325865","type":"posted-content","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T01:50:20Z","timestamp":1745373020000},"source":"Crossref","is-referenced-by-count":0,"title":["Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome"],"prefix":"10.64898","author":[{"given":"David H.","family":"McDermott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamik","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Velez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Liang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan C.","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica G.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A.","family":"Castelo-Soccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025042410251776000_2025.04.19.25325865v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.12.1133"},{"key":"2025042410251776000_2025.04.19.25325865v1.2","doi-asserted-by":"crossref","unstructured":"Beaussant Cohen S , Fenneteau O , Plouvier E , et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71.","DOI":"10.1186\/1750-1172-7-71"},{"issue":"5","key":"2025042410251776000_2025.04.19.25325865v1.3","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2019.01.045","article-title":"Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies","volume":"7","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025042410251776000_2025.04.19.25325865v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00665-w"},{"issue":"1","key":"2025042410251776000_2025.04.19.25325865v1.5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12719","article-title":"WHIM syndrome: Immunopathogenesis, treatment and cure strategies","volume":"287","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"2025042410251776000_2025.04.19.25325865v1.6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MOH.0000000000000554","article-title":"Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome","volume":"27","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"2025042410251776000_2025.04.19.25325865v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01312-7"},{"key":"2025042410251776000_2025.04.19.25325865v1.8","doi-asserted-by":"crossref","unstructured":"Garcia-Carmona Y , Chavez JL , Gernez Y , Geyer JT , Bussel JB , Cunningham-Rundles CMDP . Unexpected Diagnosis of WHIM syndrome in Refractory Autoimmune Cytopenia. Blood Adv. 2024.","DOI":"10.1182\/bloodadvances.2024013301"},{"key":"2025042410251776000_2025.04.19.25325865v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/ng1149"},{"key":"2025042410251776000_2025.04.19.25325865v1.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2289"},{"key":"2025042410251776000_2025.04.19.25325865v1.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2010.01210.x"},{"key":"2025042410251776000_2025.04.19.25325865v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.02.006"},{"key":"2025042410251776000_2025.04.19.25325865v1.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368084"},{"issue":"1","key":"2025042410251776000_2025.04.19.25325865v1.14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10875-021-01155-8","article-title":"Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome","volume":"42","year":"2022","journal-title":"J Clin Immunol"},{"key":"2025042410251776000_2025.04.19.25325865v1.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4370"},{"issue":"2","key":"2025042410251776000_2025.04.19.25325865v1.16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the Treatment of WHIM Syndrome","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"2025042410251776000_2025.04.19.25325865v1.17","doi-asserted-by":"crossref","unstructured":"McDermott DH , Velez D , Cho E , et al. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. J Clin Invest. 2023;133(19).","DOI":"10.1172\/JCI164918"},{"issue":"1","key":"2025042410251776000_2025.04.19.25325865v1.18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.2023022658","article-title":"A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome","volume":"144","year":"2024","journal-title":"Blood"},{"key":"2025042410251776000_2025.04.19.25325865v1.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527226"},{"key":"2025042410251776000_2025.04.19.25325865v1.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1908"},{"key":"2025042410251776000_2025.04.19.25325865v1.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403378"},{"issue":"8","key":"2025042410251776000_2025.04.19.25325865v1.22","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1172\/JCI120375","article-title":"Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model","volume":"128","year":"2018","journal-title":"J Clin Invest"},{"issue":"12","key":"2025042410251776000_2025.04.19.25325865v1.23","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.2200871","article-title":"Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs","volume":"210","year":"2023","journal-title":"J Immunol"},{"key":"2025042410251776000_2025.04.19.25325865v1.24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M309546200"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.04.19.25325865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:34:18Z","timestamp":1768509258000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.04.19.25325865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1101\/2025.04.19.25325865","relation":{},"subject":[],"published":{"date-parts":[[2025,4,22]]},"subtype":"preprint"}}